The following were selected from among 130 abstracts for oral presentation during the 5th Annual ENETS Conference held in Paris in March 2008. The authors in bold were awarded monetary prizes during the conference. Clinical Research
Annamaria Colao et al, Naples, Italy. Epidemiology of gastro-enteropancreatic and thoracic NET: Data from a large multicentric Italian database (NET management study)
Giulia Franchi et al, Milan, Italy. Predictors of biological behavior in pancreatic endocrine tumors: Analysis of 236 patients Saila Kauhanen, et al, Turku, Finland. 18F-FDOPA PET for detection of neuroendocrine tumors – Single-institution experience
Ulrich-Frank Pape, et al, Berlin, Germany. Prognostic relevance of the novel TNM-classification system for neuroendocrine tumors of mid-and hindgut origin Vikas Prasad, et al, Bad Berka, Germany. Response assessment after Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized neuroendocrine tumors (NET): Comparison of metabolic (F-18-FDG), receptor (Ga-68-DOTA-NOC) PET/CT and CT alone Rajaventhan Srirajaskanthan, et al, London, Great Britain. Comparison of 68Ga-octreotate-PET and (111In)-pentetreotide scintigraphy (OctreoscanTM)-Spect in patients with neuroendocrine tumors
Basic Research
Christian Prinz et al, Munich, Germany. Expression of MMPs and TIMPs in midgut carcinoids, lymph nodes and liver metastases Colette Roche, et al, Lyon, France. The PI3 kinase-m-TOR-p70S6K pathway is a target to inhibit proliferation in the intestinal endocrine cell line STC-1 Viktor Johanson, et al, Gothenborg, Sweden. CHS 828 as radiosensitizer in peptide receptor radionuclide therapy of xenografted human midgut carcinoid tumors Ola Nilsson, et al, Gothenborg, Sweden. Recurrent chromosomal aberrations in ileal carcinoids demonstrated by high-resolution array CGH Rosario Pivonello, et al, Naples, Italy. Expression of somatostatin and dopamine receptors and effect of chimeric somatostatin-dopamine molecules on cell proliferation in pancreatic neuroendocrine tumors
Matthias Schott, et al, Düsseldorf, Germany. Immunotherapy with xenogenic polypeptide hormone induces tumor rejection in a transgenic mouse model for neuroendocrine cancer